about
Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamilCurrent perspectives on congenital long QT syndrome.Current review of Brugada syndrome: from epidemiology to treatment.Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study.Dynamic Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy Revisited: Significance, Pathogenesis, and Treatment.Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy.Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction.An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy.Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair.Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy.Hypertrophic cardiomyopathy with massive midventricular hypertrophy, midventricular obstruction and an akinetic apical chamber.Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment.Echocardiography in the treatment of hypertrophic cardiomyopathy.Pacing in obstructive hypertrophic cardiomyopathy: a therapeutic option?Reflections of inflections in hypertrophic cardiomyopathy.Echocardiography to individualize treatment for hypertrophic cardiomyopathy.A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?Preparticipation athletic screening for genetic heart disease.Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy.Misconceptions and Facts About Hypertrophic Cardiomyopathy.Drug Therapy for Hypertrophic Cardiomypathy: Physiology and PracticeThe Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context.Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.Pharmacologic Therapy of Hypertrophic Cardiomyopathy.Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy.State Requirements for Automated External Defibrillators in American Schools: Framing the Debate About Legislative Action.Reversal of acute systolic dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical relief of obstruction.Onset during exercise of spontaneous coronary artery dissection and sudden death. Occurrence in a trained athlete: case report and review of prior cases.Doppler Systolic Signal Void in Hypertrophic Cardiomyopathy: Apical Aneurysm and Severe Obstruction without Elevated Intraventricular Velocities.Isometric handgrip exercise during dobutamine-atropine stress echocardiography increases heart rate acceleration and decreases study duration and dobutamine and atropine dosage.Implantable cardioverter-defibrillators for children and adolescents at high risk for sudden death from hypertrophic cardiomyopathy.Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy.Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up.Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy.Mitral valve coaptation and its relationship to late diastolic flow: A color Doppler and vector flow map echocardiographic study in normal subjects.Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy.The surgical management of obstructive hypertrophic cardiomyopathy: the RPR procedure-resection, plication, release.Severe symptoms in mid and apical hypertrophic cardiomyopathy.
P50
Q28291384-6DA944C0-2C2D-4D7F-8424-C6898AE930BEQ33158272-5823436A-1949-4E82-A77D-26A1A9590343Q33158275-9A018D8E-2E72-44D8-99BD-97BAF01D16C2Q33161115-1A661BE6-E41B-493F-B66C-5E8A713B7854Q33863573-1CCAB4AD-504C-48D2-9E26-AEAC2129DC0AQ33921103-998FAB68-AE7F-4FB6-B519-2DBAC47A9671Q34180085-52784A91-68B3-4A0E-9A28-FFE64E342713Q34353109-E7B8184A-E3CF-4F0F-B83B-05E17E8EC23FQ34428581-9BB874A9-8ADF-4111-85E5-D268F6548B77Q34543914-7C1D0E0F-28D7-4CD4-91FF-7D73590C67C3Q36581911-94FDAB60-30F5-4C14-87E6-21B4607CB756Q36680501-8D0F48BB-8E09-4D00-984D-5DEEDCC801F0Q36680505-BB8B40E9-E527-4A2E-9293-05193CA802E4Q36680533-E5964F06-E51A-424B-8D6D-FCFD87EA2767Q37546332-3223C791-E8A8-410A-BD17-21AC2726EC49Q38017805-0AEDF2DE-B22A-48CF-9FBE-B7AE8C532B08Q38017807-39CEC210-3835-4DFE-A7B7-A87DD0545850Q38017816-8C083BF9-AB03-4324-81D4-1451046E47B1Q38017817-1D608609-F21C-4BEB-95CE-BD3CDC20ED4EQ38031711-53AF816C-0607-4A17-8A44-2EC4E3F0ECA1Q38572004-D8998C51-6F63-4FCB-83ED-9A2040340F9FQ38714348-DBA6E376-E3E5-4CC6-81F5-2557671811C4Q38808937-0E8EB510-CACF-4434-9884-A0E301F010DFQ38895391-6643B5BD-B168-4A0C-92A5-66C797B7EBCFQ39183934-9963AE9C-0334-46DA-AC9E-EADB53307AA7Q39184949-D865CA0E-0897-417B-9119-8DB606A4CE4FQ39209227-3AC351F3-9214-47AB-B2BC-E853434F1CA5Q39261778-F1E1C320-AC0C-4831-A472-DCB899B9E304Q40442441-3FA160D3-2F38-4CB6-BF7B-6F9CC42BA621Q41284884-19D971F0-125D-427A-B101-94B1BAB0D9EAQ44455444-DCDC9CEB-0021-4FD8-8CC0-217998A30B3FQ44536600-85D4F47F-C828-453F-81EA-C5C5B4D1ED64Q45208218-2B045D15-13F4-4389-B44D-2ACB0780D838Q45767563-FCC8D8D0-97EB-47EC-8EE4-9ED906D30B82Q46609433-20B88E75-C0A2-4E1C-8FA2-BF4671831CDFQ47140449-509667C9-F682-46CB-9E53-2AA1588D6E64Q48046167-4C16F6AB-F73E-4E83-B779-599D0E3B6517Q48602646-E02BEF78-6433-4BBC-82CD-33628BB20142Q49864661-0BA4FBA3-D6BB-43AC-AD7F-4565653E73FEQ51599093-A12ED9D2-EBD1-469E-BF6F-132ACCC6254D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark V Sherrid
@ast
Mark V Sherrid
@en
Mark V Sherrid
@es
Mark V Sherrid
@nl
Mark V Sherrid
@sl
type
label
Mark V Sherrid
@ast
Mark V Sherrid
@en
Mark V Sherrid
@es
Mark V Sherrid
@nl
Mark V Sherrid
@sl
altLabel
Mark V Sherrid
@en
Mark V. Sherrid
@en
prefLabel
Mark V Sherrid
@ast
Mark V Sherrid
@en
Mark V Sherrid
@es
Mark V Sherrid
@nl
Mark V Sherrid
@sl
P106
P21
P31
P496
0000-0003-4972-7780